Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rob White

Anticipating the future in healthcare

New technologies will be key drivers for change

National Institute for Health and Care Excellence NICE logo

NICE system ‘slowing market access to cancer meds’

Two new reports show that UK access to new treatments and survival rates among lowest in Europe

- PMLiVE

Transforming times at AstraZeneca

Lisa Anson, the company’s UK and Ireland president, on AZ's future direction

- PMLiVE

Future gazing: What does 2015 hold for NICE?

Undermined by the CDF, the Institute is set to face a number of challenges this year

- PMLiVE

Communicating value

The global recession has changed the way the industry needs to market its medicines

- PMLiVE

England’s Cancer Drugs Fund: Fixing a broken system

Following the culling of 16 medicines from the Fund PME looks at how to improve market access for new oncology products

- PMLiVE

First biosimilar Humira launches in India

AbbVie to face competition for world’s biggest-selling drug

- PMLiVE

Cancer drugs lead SMC recommendations

New treatments from Roche, Lilly and Celgene backed for use in Scotland

- PMLiVE

OPEN Health launches market access division

OPEN Access Consulting will be headed by Cathy Wright and Cathy Jarrold

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

- PMLiVE

Market access and the importance of early stakeholder engagement

Join the webinar on December 10

- PMLiVE

Novo Nordisk’s Klaus Henning Jensen on trends in medical affairs

PMLiVE speaks to the head of clinical, medical and regulatory for Novo in the UK and Ireland

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links